A Study to Evaluate Effectiveness & Safety of Deucravacitinib in

See also
Status	Clinical Trial	Phase
Completed	`NCT04720105` - Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis	Phase 4
Completed	`NCT01197976` - Efficacy Study of TEPSO® Socks in Improving Palmoplantar Psoriasis	Phase 2
Completed	`NCT00629772` - Safety and Efficacy of Infliximab in Palmoplantar Psoriasis	Phase 3
Not yet recruiting	`NCT04622033` - Brodalumab in Palmoplantar Psoriasis	Phase 4

See also

Status

Clinical Trial

Phase

Completed

NCT04720105 - Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

Phase 4

Completed

NCT01197976 - Efficacy Study of TEPSO® Socks in Improving Palmoplantar Psoriasis

Phase 2

Completed

NCT00629772 - Safety and Efficacy of Infliximab in Palmoplantar Psoriasis

Phase 3

Not yet recruiting

NCT04622033 - Brodalumab in Palmoplantar Psoriasis

Phase 4

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT06042920
Study type	Interventional
Source	Bristol-Myers Squibb
Contact	First Name: BMS Study Connect Contact Center Last Name: www.BMSS
Phone	855-907-3286
Email	Clinical.Trials@bms.com
Status	Recruiting
Phase	Phase 4
Start date	October 10, 2023
Completion date	April 22, 2026

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms